

University of Alabama at Birmingham UAB Digital Commons

All ETDs from UAB

**UAB Theses & Dissertations** 

2014

# Detection of Scardovia genus from oral samples in children using real-time quantitative polymerase chain reaction

Jungyi Alexis Liu University of Alabama at Birmingham

Follow this and additional works at: https://digitalcommons.library.uab.edu/etd-collection

#### **Recommended Citation**

Liu, Jungyi Alexis, "Detection of Scardovia genus from oral samples in children using real-time quantitative polymerase chain reaction" (2014). *All ETDs from UAB*. 2318. https://digitalcommons.library.uab.edu/etd-collection/2318

This content has been accepted for inclusion by an authorized administrator of the UAB Digital Commons, and is provided as a free open access item. All inquiries regarding this item or the UAB Digital Commons should be directed to the UAB Libraries Office of Scholarly Communication.

## DETECTION OF SCARDOVIA GENUS FROM ORAL SAMPLES IN CHILDREN USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION

by JUNGYI ALEXIS LIU

# NOEL K. CHILDERS, COMMITTEE CHAIR AMJAD JAVED GARY R. CUTTER WU HUI

## A THESIS

Submitted to graduate faculty of The University of Alabama at Birmingham, In partial fulfillment of the requirements for the degree of Master of Science

**BIRMINGHAM, ALABAMA** 

Copyright by JUNGYI ALEXIS LIU 2014

## DETECTION OF SCARDOVIA GENUS FROM ORAL SAMPLES IN CHILDREN USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION

JUNGYI ALEXIS LIU

#### DENTISTRY

## ABSTRACT

Streptococcus mutans (Sm) and Streptococcus sobrinus (Ss), are considered the major bacterium associated with dental caries. However, recent findings identify Scardovia species (Sc) is associated with early childhood caries, with or without the presence of Sm or Ss. This IRB approved study quantified the presence of Sm and Sc in saliva by real-time quantitative PCR (gPCR) in relation to caries. Saliva samples were collected from 72 preschool children in a high-caries risk community in rural Alabama. SYBR Green-based qPCR using extracted DNA and primers specific for Sm, Ss, Sc and total bacteria determined the copy number (CN/ml). Twenty two subjects (30.6%) were in caries-free group (DMFS/dmfs=0), whereas 50 (69.4%) subjects in caries-experience group (DMFS/dmfs>0). The detection limited for quantification was determined to be 1000 CN/ml. Sc was detected in 72.8% in the caries-free group and 80% of subjects in the caries-experience group. Sm was ubiquitous (approached 100%) in both groups. None of the samples had quantitatable levels of Ss. Generally, the level of Sm was much higher than Sc. Although the caries-experience group had higher mean ratio of Sm/total bacteria and Sc/total bacteria than children in caries-free group, the only significant difference between the two groups was found in the mean ratio of Sc/total bacteria (p=0.022). No statistical difference was found in detection frequency between caries-experience and caries-free group in the three different bacterial combination groups (Sc negative+ Sm negative, Sc negative+ Sm positive, Sc positive+ Sm positive). The overall results indicated that Sc was highly detected in caries-experience group and the ratio of Sc/total bacteria was significantly associated with caries history. Although the presence of Sm, Sc or the combination of both bacteria didn't show correlation to caries, other diet & dietary practices, ethnicity, oral hygiene factors, factors (e.g., socioeconomic influences, host factors and general health conditions, medications) must also be considered since caries is a multifactorial disease.

Keywords: real-time quantitative PCR, S. mutans, Scardovia, dental caries

iv

## DEDICATION

This thesis is dedicated to my family; my mother, Ping-ping Miao; my brother: Timothy Liu and my father, Siou-shing Liou. Thank you for always being there to support me and encourage me to fulfill my dream to study aboard. It is also dedicated to my boyfriend; Chih-liang Tien. Thank you for always being with me when things are difficult. Thank you all for the supports and encouragement that I got from you all. I couldn't finish this without your help and support.

### ACKNOWLEDGEMENTS

I would like to thank ...

My research mentor, Dr. Childers, for guiding me throughout my graduate study and inspire my interest in microbiology. Thank you for being so supportive in my graduate study.

My research committee, Dr. Wu, Dr. Cutter, Dr. Javed, for providing generous support and advice for my master degree project and thesis.

Dr. Chanika Manmontri, Dr. Jing Zou, Dr. Qiang Cheng, Dr. Hernan E Grenett, for helping with the testing and designing of primers for that are the foundation of this study. Thank you for all your hard-efforts to teach and guide me through this project.

All the clinical and laboratory participants of this study: Mary Slater, Frances Jackson, Tonya Wiley, Dr. Steve Mitchell, Dr. Sonia Makhija, Dr. Rosalyn Bassett, and all the hard-working pediatric dental residents of the UAB School of Dentistry. Thank you for your diligence and participation in the ongoing Uniontown project. Support from 3M ESPE Preventive Pediatric Dentistry Postdoctoral Research Fellowship, Dr. Britta Rahemtulla Endowed Scholarship Fund Award, the UAB Graduate School Fellowship. Thank you for recognizing me and supporting

vi

scholarship for this study. Besides, this project was also supported by a Research Grant DE016684 from the National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.

## TABLE OF CONTENTS

Page
------

ABSTRACT	iii
DEDICATION	v
ACKNOWLEDGEMENTS	vi
LIST OF TABLES	x
LIST OF FIGURES	xi
LIST OF ABBREVIATIONS	xii
INTRODUCTION	1
Streptococcus mutans and Dental Caries Other Bacteria Associated with Caries Scardovia wiggsiae and Dental Caries Real-time Quantitative Polymerase Chain reaction Studies using qPCR for Detection and Quantification of Scardovia	3 5 6 8 9
SPECIFIC AIM	11
MATERIALS AND METHODS	12
Study Population Sample Collection Oral Examination Isolation of DNA from Oral Samples PCR Primers Real-time Quantitative PCR Statistics.	12 13 13 14 14 16 18
RESULTS	20
Detection Frequency and Bacterial Level of All Samples Bacterial Level and its Correlation to Caries Detection Frequency in Caries-experience and Caries-free Group Bacterial Level in Caries-experience and Caries-free Group	20 21 22 23
DISCUSSION	29

Limitation	33
CONCLUSION	35
REFERENCES	36
APPENDIX: IRB APPROVAL FORMS	42

## LIST OF TABLES

Table	Page
1 Primers used in the study	15
2 Mean, standard deviation, median of Sm, Ss and Sc from all subjects	21
3 Spearman correlation value between bacterial level and DMFS/dmfs inde	əx22
4 Bacterial level in caries-experience and caries-free group and t-test analy	ysis24
5 Bacterial level in caries-free group and active caries group with	ו t-test
analysis	26
6 Bacterial ratio and DMFS/dmfs index in caries-experience group with Sc	and/or
Sm with ANOVA analysis	27

## LIST OF FIGURES

Figure	Page
1 Standard curve of S. wiggsiae	17
2 Detection frequency of Sm, Sc, Sm+Sc in caries-experience and	d caries-free
group	23
3 Mean ratio of bacteria in caries-experience and caries-free group	25
4 Sm and/or Sc combinations in the caries-experience and caries-free	groups28

## LIST OF ABBREVATIONS

CN	Copy number
Cq	Quantification cycle
DMFS	Decay, missing, filled surface score in permanent teeth
dmfs	Decay, missing, filled surface score in primary teeth
DMFT	Decay, missing, filled tooth score in permanent teeth
dmft	Decay, missing, filled tooth score in primary teeth
DNA	Deoxyribonucleic acid
gtf	Glucosyltransferases
ECC	Early childhood caries
HIV	Human immunodeficiency virus
MS	Mutans streptococci
NHANES	National Health and Nutrition Examination Survey
PCR	Polymerase chain reaction
qPCR	Real-time quantitative polymerase chain reaction
RTF	Reduced transport fluid
Sc	Scardovia
S.D.	Standard deviation

# LIST OF ABBREVATIONS (Continued)

S-ECC	Severer early childhood caries
Sm	Streptococcus mutans
Ss	Streptococcus sobrinus
Sw	Scardovia wiggsiae
TE buffer	Tris-EDTA buffer
Tm	Melting temperature
UAB	the University of Alabama at Birmingham

## INTRODUCTION

Dental caries is the most common chronic disease that affects children in the United States (US)<sup>1, 2</sup>. According to the data from National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2004, dental caries is increasing among children aged 2–5 years<sup>1</sup>. The prevalence of caries was found to be 24% in children 2-5 years old in 1988-1994, and increased to 28% in 1999-2004<sup>1</sup>. The increasing rate between 1988–1994 and 1999–2004 was seen in numbers of restored dental surfaces (not untreated caries). This finding indicates that the increase in caries under 6 years old may be due to receiving more dental treatment<sup>3</sup>.

According to guidelines from the American Association of Pediatric Dentistry, children are classified as having severe early childhood caries (S-ECC) if they present with more than 1 cavitated, missing (due to caries), or filled smooth surface in primary maxillary anterior teeth at age 3 to 5 or with a dmfs (decay, missing, filled surface) score of more than 4 at age 3, more than 5 at age 4, or more than 6 at age 5<sup>4</sup>. For children under three years old, any caries on smooth tooth surface is also classified as S-ECC. The impact of S-ECC in the United States cannot be underestimated. It not only affects the quality of life for the

children, but also may affect their families because of financial, educational, and social costs<sup>5,6,7</sup>. Untreated dental caries can result in a range of negative outcomes, from chronic pain to severe infection, threatening the child's life. Dental pain can also cause long-term problems for children with eating, speaking, and school attendance/performance. Treatment for S-ECC often requires full mouth rehabilitation with extensive treatment. For example, a 1996 study in Northern California<sup>8</sup> showed the cost of dental treatment for dmft (decay, missing, filled tooth) score 2-5 was \$408 to \$1725 for dmft score 16-20. According to the study, many patients failed to finish treatment because of the cost, and prices for these procedures are undoubtedly higher now. Due to uncooperative behavior of children at a young age, general anesthesia or deep sedation may be required for dental treatment, resulting in even higher costs. For example, one study from Louisiana reported that the cost for dental treatment in the hospital operating room was as much as fifteen times more than treatment that did not use general anesthesia<sup>9</sup>. In order to treat and prevent dental caries effectively, it is important to know the etiology of caries, including the bacteria that are associated with this infectious disease.

There are three main hypotheses for the cause of dental caries: the nonspecific plaque hypothesis, the specific plaque hypothesis, and the ecological plaque

hypothesis<sup>10-12</sup>. The nonspecific plaque hypothesis suggests that plaque, the accumulation of bacteria, is the cause of dental caries and that there is no bacteriological difference between plague from a carious lesion and a non-carious lesion. However, the composition of plaque can vary from site to site. The specific plaque hypothesis states that the accumulation of certain bacteria, such as Streptococcus mutans, causes caries. The third hypothesis, the ecological plaque hypothesis, proposes that caries can be explained as a result of dynamic changes in the environment of dental plaque. Excess sugar intake results in acids production, then leads to the changes of pH value in the environment of plaque. This new environment encourages the growth of acidogenic and aciduric species and causes a shift in the balance of the microflora and resulting demineralization in tooth enamel. Most recent research focuses on this ecological theory to determine the diversity and complexity of the microbiota of dental caries biofilm.

## Streptococcus mutans and Dental Caries

Mutans streptococci (MS) including *Streptococcus mutans* and *streptococcus sobrinus* play an important role in the initiation and development of dental caries <sup>13, 14, 15, 16</sup>. In Hughes' study<sup>17</sup>, the *S. mutans* and *S. sobrinus* levels are associated with S-ECC via culture method. Other studies also show similar

association by molecular analysis<sup>18, 19</sup>. Several publications demonstrate that the quantity of S. mutans obtained from clinical samples has high association with dental caries prevalence<sup>20,21,22,23</sup>. The unique feature that makes S. mutans so important in caries development and progression is its acidogenic and aciduric properties. It can produce acid to demineralize enamel tooth surfaces which make them is susceptible to surface breakdown and caries. Moreover, S. mutans not only survives, but actually thrives in the low pH environment resulting from the acidic environment produced. S. mutans can adhere to the enamel salivary pellicle coated by saliva<sup>24</sup>. Glucosyltransferases (GTFs) enable S. mutans to metabolize sucrose and produce a sticky, extracellular, dextran-based polysaccharide that provide a further and stronger adhesion to tooth surface<sup>25</sup>. This is due to the sticky nature of these polysaccharides, that facilitates the adherence of S. mutans to the tooth and resist its detachment by normal forces like mastication, swallowing or chewing<sup>26</sup>. S. mutans not only metabolize sucrose but also utilize other sugars, such as glucose, fructose, lactose via glycolysis which produce lactic acid as the end product<sup>27</sup>.

## Other Bacteria Associated with Caries

Although *S. mutans* and *S. sobrinus* are considered the major bacterium associated with dental caries, recent findings conflict with the concept that proposes *S. mutans'* uniquely prominent role<sup>27, 28</sup>. It has been reported that some individuals with dental caries did not possess high levels of *S. mutans*. From one study by Aas<sup>28</sup>, 10-15% of caries-active subjects do not have detectable levels of *S. mutans*. Thus, the presence of the *S. mutans* does not necessarily indicate caries activity. The authors<sup>27</sup> also point out that 10 to 20% of subjects with severe caries may not have detectable *S. mutans*, but rather exhibit other acid-producing bacteria species.

Several analyses<sup>28, 29</sup> report that *S. mutans* commonly occurs in low proportion compared to the total count of microbiota biofilm. These reports also show that there may be other bacteria associated with dental caries. Becker<sup>29</sup> and colleagues, in a 2002 analysis, compared the microbial content from children with early childhood caries (ECC) to caries-free children using molecular identification methods. They concluded that other bacteria, such as *Actinomyces gerencseriae* and other *Actinomyces spp.*, may be associated with the initiation of caries. They also found that *Bifidobacterium* may be dominant in deep caries. Using cultural and molecular techniques, Munson<sup>30</sup> and his colleagues isolated *S. mutans*,

Propionibacterium sp., Lactobacillus gasseri/ johnsonii, Lactobacillus rhamnosus, and Olsenella profuse from adults with carious lesions. They indicated there are some new species found in carious lesions and concluded that *S. mutans* is not the main bacteria causing caries.

## Scardovia wiggsiae and Dental Caries

One possible explanation for the findings that caries is not always associated with *S. mutans* is that there may be other important cariogenic bacteria that are responsible for the pathogenicity of caries. With the advancement of molecular techniques, recent findings have demonstrated a newly identified/named bacteria; *Scardovia wiggsiae,* which has been associated with ECC without the presence of *S. mutans*<sup>29, 31, 32</sup>. This new species was previously classified as an unidentified *Bifidobacterium species*.

*Scardovia wiggsiae*, was named in honor of Lois Wiggs, an American microbiologist, for her contributions to anaerobic microbiology. Like *S. mutans*, *S. wiggsiae* bacteria is acidogenic and aciduric. It is gram-positive, anaerobic (facultative), non-spore-forming and non-motile bacilli. *S. wiggsiae* is saccharolytic and produce acetic and lactic acids as end products of fermentation<sup>33</sup>. An animal study with *S. wiggsiae* concluded that *S. wiggsiae* has the cariogenic traits of

acidogenicity and acid tolerance, and it is associated with caries. However, as a single species it was not cariogenic in the animal model system as tested<sup>34</sup>.

Becker and his colleagues<sup>29</sup> reported that *S. wiggsiae* is associated with advanced dentinal caries in young children, and also can be found in white spot lesions. S. wiggsiae is also reported to be found in advanced dentinal caries in adults<sup>6</sup>. In 2009, Mantzourani<sup>35</sup> isolated *S. wiggsiae* from occlusal carious lesions from adults and children. Tanner<sup>31</sup> showed that a combination of *S. wiggsiae* and S. mutans is highly associated with S-ECC via sequence-based analysis of the 16S rRNA from culture isolates. Tanner also found that S. wiggsiae was associated with S-ECC in the absence of S. mutans in their preliminary study<sup>31</sup>. The possible explanation is that *S. wiggsiae* is involved in caries when it extends into dentin<sup>31</sup>. Later Tanner developed traditional PCR method to detect S. wiggsiae to supplement their previous findings related to caries<sup>36</sup>. They found that S. wiggsiae was more strongly association with S-ECC than S. mutans. These findings suggested the need for further studying the relation of high caries-risk groups with this species.

#### Real-time Quantitative Polymerase Chain reaction

There are various ways to detect bacteria in oral samples. Traditional methods to identify bacteria are based on phenotypic identification using gram staining, culture and biochemical methods. However, these methods have the limitation that this method can only be used only for organisms that can be cultivated in vitro. Molecular techniques have proven beneficial in overcoming some limitations of traditional phenotypic procedures for the detection and characterization of bacterial phenotypes<sup>21</sup>.

Real-time polymerase chain reaction (qPCR) is used to amplify and quantify a targeted DNA using species or genus specific primer sets. The difference between qPCR reaction and traditional PCR is that the qPCR amplified DNA is detected as the reaction progresses in "real time". The amplification products in qPCR are measured using a fluorescent label. There are several methodologies for florescent label (i.e., TaqMan, Molecular Beacons, SYBR Green). The most economic method is SYBR Green. The amount of DNA is measured after each cycle via SYBR Green dye which bind to any double-stranded DNA such that increasing fluorescent signal results which is proportional to the number of PCR product molecules (amplicons) generated. In traditional PCR, detection and quantification of the amplified sequence are performed at the end of the reaction

after the last PCR cycle via electrophoresis and image analysis.

qPCR is used to rapidly detect and quantify bacterial from samples<sup>37</sup>. Studies show that qPCR is more sensitive in detecting bacteria than traditional culture methods<sup>19, 38</sup> as well as conventional PCR<sup>39</sup>. qPCR does not limit the detection to live bacteria. Therefore, it overcomes the inability of detecting nonviable bacteria when using the culture method. Samples for qPCR can be handled easily and remain stable over long time periods, especially upon freezing. This advantage can be a great benefit for handling large numbers of samples in epidemiologic studies<sup>40</sup>.

## Studies using qPCR for Detection and Quantification of Scardovia

Several studies have used qPCR for detecting and quantifying MS from oral samples<sup>19,18, 20, 21, 41</sup>. However, to date there is only one study<sup>42</sup> that reports using qPCR to detect *S. wiggsiae* from clinical samples. Tanner<sup>42</sup> et. al., found an association of *S. wiggsiae* with white spot lesion in orthodontic patients.

According to the literature, *S. wiggsiae* may be present in oral samples and may contribute to the etiology of dental caries. The purpose of this study is to use qPCR to detect and quantify MS and *S. wiggsiae* in oral samples from high-caries-risk children in Alabama. We hypothesize that participants with caries

and low level of *S. mutans* will have a higher proportion of *S. wiggsiae*. To test our hypothesis, we isolated DNA samples from high caries-risk children in Uniontown, Alabama, a rural high caries risk community. Species-specific qPCR was used to detect *S. wiggsiae, S. mutans and S. sobrinus.* The findings are important to dental research and treatment because successful evaluation of the presence of *S. wiggsiae* may be a useful caries-risk assessment tool.

## SPECIFIC AIMS

- 1. To develop a sensitive and specific assay using qPCR for Scardovia genus detection and quantification from clinical samples.
- 2. To study the correlation between the level of Scardovia genus in clinical samples and caries prevalence.
- 3. To compare the level of Scardovia and MS in clinical samples relative to correlation with caries prevalence.

## MATERIAL AND METHOD

#### **Study Population**

The sample population was from a low socioeconomic, high caries risk community in Perry County, Alabama. Subjects are part of an ongoing longitudinal epidemiological study in this rural community. The subjects were pre-school children who had no regular access to dental care in the county. Oral samples from 72 children were included in this study. Children included in this study were free of systemic diseases, i.e., genetic and birth defects, kidney disorders, hepatitis. bleeding disorders. disorders, cancer. endocrinal epilepsy, immunodeficiencies, heart condition, heart murmur, bone disorders, HIV positive, or immunosuppressant drugs users. This study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board. Parents of participating subjects were provided with and signed informed consent and signed wavier of assent (i.e., for the children due to age) for sample collection, oral examination and questionnaire completion. The questionnaire included survey of medical history, diet and nutrition practices, oral hygiene and dental history.

## **Oral Examination**

Oral examination by trained and calibrated examiners was performed using light source, compressed air source or 2x2 gauze, mirror and explorer (limited for confirmatory use only); no radiographs were taken. Dental status was diagnosed and scored as decayed, missing, filled surface score (DMFS/dmfs index) according to WHO criteria<sup>43</sup>.

## Sample Collection

Saliva samples were collected from each child for qPCR analysis using sterile cotton swab placing in the mouth and rubbing along checks, tongue and teeth until saturated with saliva, then placed into 4.5 mL reduced transport fluid<sup>44</sup>. These saliva samples were estimated to be diluted approximately 1:70 (determined by pilot study of weight of saliva absorbed by cotton swabs). After collection, all samples were stored on ice while being transported approximately 100 miles to UAB School of Dentistry. The samples were processed within 24-36 hours of collection for bacterial DNA extraction.

## Isolation of DNA from Oral Samples

One milliliter of oral sample was used for DNA extraction and purification with MasterPure<sup>™</sup> Gram Positive DNA Purification Kit (Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer's instruction. After isolation, the DNA was re-suspended in 35 µl of Tris-EDTA Buffer (TE Buffer). Therefore, this volume resulted in a 28.5-fold concentration of the DNA sample (i.e, from 1 ml sample).

## **PCR** Primers

The extracted DNA from clinical samples were used as a template for qPCR using species-specific primers for *S. mutans*, *S. sobrinus*, Scardovia and total bacteria (Table 1).

|--|

Species	Soquenee	Amplicon	Torgot	Source or
Species	Sequence	size (bp)	laiget	reference
Scardovia	Scar448-Foward:			
genus	5'-GTGGACTTTATGAATAAGC-3'	146 hp		Tanner,
	Scar619-Reverse:	146 bp	105 IRINA	2011 <sup>36</sup>
	5'-CTACCGTTAAGCAGTAAG-3'			
S. mutans	Smut3368-Foward:			
	5'-GCCTACAGCTCAGAGATGCTATTCT-3'	114 hn	atfD	Yoshida,
	Smut3481-Reverse:	114 bp	див	2003 <sup>45</sup>
	5'-GCC ATACACCACTCATGAATTGA-3'			
S. sobrinus	Ssob287-F:			
	5'-TTCAAAGCCAAGACCAAGCTAGT-3'	00 hn	gtfT	Yoshida,
	Ssob374-R:	00 nh		2003 <sup>45</sup>
	5'-CCAGCCTGAGATTCAGCTTGT-3'			
Universal	Forward:			
primer	5-TCCTACGGGAGGCAGCAGT-3	166 hp		Nadkarni,
	Reverse:	400 bh	103 IKINA	2002 <sup>46</sup>
	5-GGACTACCAGGGTATCTAATCCTGTT-3			

The primers for *S. mutans* and *S. sobrinus* were specifically targeted for gtfB and gtfT, respectively as published by Yoshida<sup>45</sup>. Scardovia primers were specifically targeted for the 16S rRNA as reported by Tanner<sup>36</sup>. Using these primers, *Scardovia inopinata* produces a slightly different amplicon than *S. wiggsiae*. Although this protocol for qPCR generated two different values in melting temperature, the melting temperature of *S. inopinata* was less than 1°C higher than *S. wiggsiae*. Therefore, the primers were not sufficient to differentiate the two species by qPCR. The protocol developed therefore, focused on identifying Scardovia genus. The universal primer set targeted the 16sRNA and was used to determine the total number of bacteria presented in samples. The bacterial specificity has been established by Nadkarni<sup>46</sup> with no amplification with human DNA sample. The specificity of all these primer sequences for *S. mutans*, *S. sobrinus*, Scardovia and Universal primers was confirmed through Basic Local Alignment Search Tool (BLAST) nucleotide analysis.

## Real-time Quantitative PCR

Using the genomic size of both *S. mutans* and *S. wiggsiae*, the single cell DNA weight in 1 molecule (m) can be calculated by using the following formula<sup>47</sup> m= n (bp)×660 (g/mole)/6 ×10<sup>23</sup> (molecules/mole). Therefore, the total DNA weight in 10<sup>9</sup> cell was then calculated for *S. wiggsiae* (C1A\_55, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) extracted DNA. The concentration of DNA from OD<sub>260/280</sub> was used to construct a standard curve for each qPCR run to estimate the "copy number" per milliliter (Figure 1). In this regard, the standards were 10-fold dilutions from  $10^7$  to  $10^3$  cells in Tris-EDTA buffer from MasterPure Gram Positive DNA Purification Kit (Epicentre Biotechnologies) and used for standard curve construct of *S. wiggsiae*. Similarly, *S. mutans* UA 159 genomic DNA was used to construct standards by 10-fold dilutions from  $10^9$  to  $10^3$  cells in Tris-EDTA buffer.



Figure 1: Standard curve of S. wiggsiae.

Standard curve of a ten-fold dilution series of known template concentrations of *S. wiggsiae* (10<sup>7</sup>CN/ml to 10<sup>3</sup> CN/ml) for determining the quantity of Scardovia in each oral sample.

PCR amplification was performed in a total reaction mixture volume of 12.5 µl. The reaction mixtures contained 6.25 µl Maxima® SYBR Green/Fluorescein qPCR Master Mix (Fermentas, USA), 0.75 µl of forward and reverse primer, 3 µl of nuclease-free water and 2.5 µl of purified DNA standard or "unknown" obtained from oral sample. An iQ5 Real-Time PCR Detection System (Bio-Rad) was used to perform the following cycling parameters for *S. mutans*, *S. sobrinus* and universal primers: samples were amplified by pre-heating (95°C, 10 min), then denaturation (95°C, 15 sec), annealing (60°C, 30 sec), and elongation (72°C, 30 sec) for 40 cycles. A final melting curve program was used the following cycling parameters: 60°C for 30 seconds, 5°C temperature changes to the end temperature of 95°C. For Scardovia genus, the cycling parameters the same except for the annealing temperature which was set at 51°C. The iQ5 Optical System Software generates quantitative cycle (Cq) values and analyzes the melting point data resulting in a cycle threshold (Ct) value, which is proportional to the DNA copy number.

#### Statistics

The levels of *S. mutans*, *S. sobrinus* and Scardovia from duplicate clinical samples was obtained by the average of results from interpolation of the standard curve (DNA extracted from prototype strains) and multiplied by the dilution factor to determine copy number per milliliter of sample. The total bacterial counts were determined using the universal primers targeting on 16S rRNA gene in qPCR assay. The ratio of *S. mutans*, *S. sobrinus* and Scardovia per total bacterial count was calculated for normalization in order to make comparisons between and among samples.

Spearman correlations were used to evaluate the correlation between the bacterial level, bacterial ratio and caries prevalence (DMFS/dmfs index)<sup>48</sup>. T-test was used to compare the mean bacterial level, mean bacterial ratio and caries

prevalence (DMFS/dmfs index) between disease categories<sup>48</sup>. Difference in detection frequency between disease categories was tested by Chi-square<sup>48</sup>. ANOVA was used to evaluate the difference between three different combination of bacteria (Sc negative+ *Sm* negative, Sc negative+ *Sm* positive, Sc positive+ *Sm* positive) in the mean bacterial level, mean bacterial ratio and caries prevalence (DMFS/dmfs index)<sup>48</sup>. The level of significance was set at p < 0.05. All analysis was done using SAS V9.2 (SAS Institute, Cary, NC, USA).

## RESULTS

Seventy-two pre-school children, average age of 4.6 years (age range 3.2- 5.8 years) participated in the study. Thirty-two subjects were males and 40 were females. The study population was comprised of 100% African American. One saliva sample was collected from each subject to use for qPCR.

### Detection Frequency and Bacterial Level of All Samples

The detection threshold of this qPCR was determined to be 1000 CN/ml based on the last dilution of the standard curve for qPCR with good linear reproducibility. *S. mutans* was detected from 97.2% of all samples (70/72) while Scardovia was found in 77.8% of samples (56/72). The mean CN/ml of samples were: *S. mutans* (3.79x10<sup>7</sup>), *S. sobrinus* (3.40x10<sup>3</sup>) and Scardovia (6.48x10<sup>6</sup>). Because *S. sobrinus* was only detected in 7 samples at levels below quantifiable limits, *S. sobrinus* was not included in any of the analyses (there were no associations noted with caries prevalence when *S. sobrinus* was detected). The mean ratio of *S. mutans*, *S. sobrinus* and Scardovia to total bacteria were 1.31%, 0.00%, 0.18%, respectively (Table 2). The average DMFS/dmfs index of the participants was 15.21 (DMFS/dmfs index range 0-90, S.D.=19.37).

	Sm	Ss	Sc	Total bacteria count	S <i>m</i> /total bacteria	Ss/total bacteria	Sc/total bacteria
Mean* (CN/ml)	3.79x10 <sup>7</sup>	3.40x10 <sup>3</sup>	6.48x10 <sup>6</sup>	2.41x10 <sup>10</sup>	1.31%	0.00%	0.18%
S.D. (CN/ml)	1.22x10 <sup>8</sup>	1.04x10 <sup>4</sup>	1.66x10 <sup>7</sup>	3.32x10 <sup>10</sup>	4.33%	0.00%	0.55%
Median (CN/ml)	1.46x10 <sup>6</sup>	0	8.07x10 <sup>5</sup>	9.18x10 <sup>9</sup>	0.02%	0.00%	0.01%

Table 2: Mean, standard deviation, median of Sm, Ss and Sc from all subjects.

\* Mean values were determined from samples that were quantitated (i.e., the denominator was the number of samples with *Sm*, *Ss*, or *Sc*).

## Bacterial Level and its Correlation to Caries

There was a positive relationship between the mean Scardovia and DMFS/dmfs index (r=0.245, p=0.038) by Spearman correlation analysis (Table 3). However, no significant correlations were found between the level of *S. mutans* to DMFS/dmfs index, ratio of *S. mutans*/total bacteria to DMFS/dmfs index (r=0.003, p=0.979), the ratio of Scardovia/total bacteria to DMFS/dmfs index (r=0.119, p=0.319), nor the combination of *S. mutans* and Scardovia to DMFS/dmfs index (r=0.029, p=0.811) (Table 3).

	Sm maan	n mean Sc mean Sm/ total bacteria	Sm/	Sc/	Sm+Sc/
	SIII Mean		total bacteria	total bacteria	
Spearman					
Correlation	0.026	0.245	0.003	0.110	0.020
Coefficient to	0.026	0.245	0.003	0.119	0.029
DMFS/dmfs					
P-value	0.828	0.038*	0.979	0.319	0.811

Table 3: Spearman correlation value between bacterial level and DMFS/dmfs index.

\* Correlation is significant at the 0.05 level (2-tailed).

#### Detection Frequency in Caries-experience and Caries-free Group

The seventy-two children were divided into caries-free group (DMFS/dmfs=0, n=22, 30.6%) and caries-experience group (DMFS/dmfs>0, n=50, 69.4%). There was no statistical difference (p>0.05) between the two groups in age, sex or body mass index. The average of decayed, missing, and filled surfaces were 0.7, 19.5, 1.7, respectively. In the caries-experience group, *S. mutans* was detected in 96% (48/50) of the samples, while Scardovia was found in 80% (40/50). In the caries-free group, Scardovia and *S. mutans* was found in 72.8% (16/22) and 100% (22/22), respectively. No statistical difference (p>0.05) was found in the detection frequency of *S. mutans*, Scardovia, *S. mutans*+Scardovia between caries-experience and caries-free group (Figure 2).



Figure 2: Detection frequency of *Sm*, Sc, *Sm*+Sc in caries-experience and caries-free group.

## Bacterial Level in Caries-experience and Caries-free Group

The average DMFS/dmfs index for the children in caries-experience group was 21.9. The mean CN/ml in caries group were: *S. mutans* (4.59x10<sup>7</sup>) and Scardovia (7.74x10<sup>6</sup>). The mean ratio of *S. mutans*, Scardovia, both *S. mutans* and Scardovia to total bacteria were 1.36%, 0.25%, 1.61%, respectively (Table 4). The mean CN/ml in caries-free group were: *S. mutans* (1.98x10<sup>7</sup>) and Scardovia (3.62x10<sup>6</sup>). The mean ratio of *S. mutan*, Scardovia and both *S. mutans* and Scardovia to total bacteria were 1.22%, 0.03%, 1.25%, respectively (Table 4).

	S <i>m</i> mean (CN/ml)	Sc mean (CN/ml)	S <i>m</i> / total bacteria	Sc/ total bacteria	Sc+Sm/ total bacteria
Caries-free group (n=22)	1.98x10 <sup>7</sup>	3.62x10 <sup>6</sup>	1.22%	0.03%	1.25%
Caries-experience group, (n=50)	4.59x10 <sup>7</sup>	7.74x10 <sup>6</sup>	1.36%	0.25%	1.61%
T-test	0.409	0.335	0.904	0.022 *	0.754

Table 4: Bacterial level in caries-experience and caries-free group and t-test analysis.

\* The level of significance was set at p < 0.05 by t-test analysis

When comparing children according to caries status, children in caries-experience group had higher level of *S. mutans*, Scardovia and higher ratio of *S. mutans*/total bacteria, Scardovia/total bacteria than children in caries-free group (DMFS/dmfs=0). However, statistical differences between two groups were found only in the mean ratio of Scardovia/total bacteria (p=0.022) (Table 4 and Figure 3).



Figure 3: Mean ratio of bacteria in caries-experience and caries-free group.

Children with active caries surfaces (decayed surfaces>0, n=12) had a higher mean ratio of Scardovia/total bacteria, but lower mean ratio of *S. mutans*/total bacteria than the children in caries-free group (DMFS/dmfs=0, n=22). However, no statistical difference was found between two groups (Table 5).

	S <i>m</i> mean (CN/ml)	Sc mean (CN/ml)	S <i>m</i> / total bacteria	Sc/ total bacteria	Sc+Sm/ total bacteria
caries-free group, DMFS/dmfs=0 (n=22)	1.98x10 <sup>7</sup>	3.62x10 <sup>6</sup>	1.22%	0.03%	1.25%
Active caries group, decayed surface>0 (n=12)	1.52 x10 <sup>7</sup>	3.99 x10 <sup>6</sup>	0.72%	0.22%	0.94%
P value*	0.791	0.894	0.644	0.377	0.287

Table 5: Bacterial level in caries-free group and active caries group with t-test analysis.

\* The level of significance was set at p < 0.05 by t-test analysis

None of the children in the caries-experience group (n=50) was found to harbor detectable Scardovia without the presence of *S. mutans*. However, 6.0% (3/50) of subjects in the caries-experience group had low level of *S. mutans* and high level of Scardovia. In our study, only 4.0% (2/50) of subjects in the caries-experience group were void of detectable *S. mutans* and Scardovia, while 80% (40/50) had both *S. mutans* and Scardovia detected. 16% (8/50) had only *S. mutans* alone. When both both *S. mutans* and Scardovia were present, the level of both bacteria and DMFS/dmfs index tended to increase. However, there was no statistical difference between three different combination of bacteria (negative Sc and *Sm*, negative Sc and positive *Sm*, positive Sc and *Sm*) by ANOVA (Table 6).

Caries-experience group (DMFS/dmfs>0)	N	Sm/total bacteira	Sc/total bacteria	DMFS/dmfs
Sm -, Sc -	2	0.00%	0.00%	3.00
Sm +, Sc -,	8	0.09%	0.00%	19.38
Sm +, Sc +	40	1.68%	0.31%	23.35
Sm-, Sc+	0			
P value*		0.859	0.752	0.273

Table 6: Bacterial ratio and DMFS/dmfs score in caries-experience group with Sc and/or *Sm* with ANOVA analysis.

\* The level of significance was set at p < 0.05 by ANOVA analysis

Further, no statistical difference was found in detection frequency between caries-experience and caries-free group in the three subgroups (Sc negative+*Sm* negative, Sc negative+ *Sm* positive, Sc positive+*Sm* positive) (Figure 4). In the caries-experience group, there was a higher porportion (55% of all subjects) that had both *S. mutans* and Scardovia. However, there were only two subjects in the group that neither species was detected (Figure 4).

Figure 4: *Sm* and/or Sc combinations in the caries-experience and caries-free groups.



## DISCUSSION

Saliva samples were collected from 72 pre-school children with high caries risk to detect and quantify S. mutans, S. sobrinus and Scardovia and its correlation to caries activity. In this study, most subjects were found to have S. mutans and Scardovia present in saliva samples. Scardovia was detected in 80% of subjects in the caries-experience group (DMFS/dmfs>0) and 72.8% in the caries-free group (DMFS/dmfs=0). According to Tanner's study in 2011<sup>31</sup>, S. wiggsiae was detected in over 50% of the children using cultural method. In a later study, S. wiggsiae was found in 36.6 - 60% by qPCR in the study of orthodontic patients with white spot lesions<sup>42</sup>. In this study, the detection rate of Scardovia was higher than was reported by others<sup>31, 42</sup>. Since our primers detected Scardovia species, not just S. wiggsiae, we may have detected other Scardovia species in our samples to account for the higher positive rate of detection. Alternatively, differences in this high risk population compared to Tanner's cohorts could account for the observation differences.

None of our subjects had quantifiable *S. sobrinus*. The differences in *S. sobrinus* detection among the present study and other studies<sup>18, 39, 49, 50</sup> might be due to different ethnicity of sample population. However, since some studies

reported *S. sobrinus* in African populations<sup>39</sup>, the lower level of *S. sobrinus* found in this study may be also due to geographical location of sample population.

This study took advantage of the ability to quantify oral samples with qPCR. We were able to quantify each bacteria to determine the correlation to dental caries data. Although the mean ratio of S. mutans (1.31%) is 7 times higher than the ratio of Scardovia (0.18%), when comparing between caries-experience and caries-free group, the ratio of Scardovia to total bacteria was the only variable that was significantly different (p=0.022) among the groups. This finding is similar to those in Tanner's 2012 study<sup>42</sup>. No statistical difference was found in other comparsions, including the consideration of S. mutans and Scardovia together (i.e., no added association was found when compared with caries status). This finding contradicts those reported in Tanner's <sup>36</sup> study where they found that the combination of S. mutans with S. wiggsiae was more strongly associated with S-ECC than when evaluated individually. The difference may be due to characteristics of the caries experience (i.e., most caries was treated) in our study population compared to Tanner's study since their observations were before caries was treated.

Several studies using qPCR for detection and quantification of MS from oral samples have reported a high association between MS findings to caries

prevalence <sup>19,18, 20, 41, 39, 50</sup>. However, in the present study we did not find a correlation between the level or the presence of *S. mutans* (nor *S. sobrinus*) to caries status. This finding, is similar to a study reported by Vieira<sup>51</sup>. They found that DMFT scores of adults didn't correlate with *S. mutans* colonization measured by real-time PCR assay. Neither was an association between the level of *S. mutans* and caries experience found in children in Acevedo's study<sup>52</sup>.

Although the average DMFS/dmfs index (DMFS/dmfs=21.9) in the caries-experience group from this study was high, the index was influenced mostly by the number of the presence of filled surfaces (mean=1.7) and missing surfaces (mean=19.5). There were only 12 subjects (24%) in caries-experience group (n=50) that had active caries (mean decayed surface=0.7). *S. mutans* is considered to be associated with the initiation of caries. It was presumed that the level of *S. mutans* would increase when new carious lesions were developing. However, the extent of dental caries when cavitated lesions were detected in the present study may be too late to detect a significant association between *S. mutans* and caries prevalence. Further, the 76% (38/50) of this cohort in the caries-experience group were with filled or missing tooth surfaces and therefore may not be associated with the initiation of caries pathogenesis.

We defined the DMFS/dmfs=0 group to be "caries-free". Even though cavitated

lesions were not observed, our data with relatively high *S. mutans* in this group may indicate we missed some caries activity (i.e., in the initial stages). This could also reflect a lack of sensitivity in caries disease detection due to lack of radiographs.

In this study, 2 subjects in the caries-experience group had no detectable *S. mutans* or Scardovia. Of these two subjects, one had active caries lesions while the other had only history of "filled" tooth surfaces. Therefore, of the subjects with active caries, only 1 of 12 (8.3%) didn't have detectable *S. mutans*. This finding may reflect what other studies have found with caries but no detectable *S. mutans*<sup>27, 28</sup>. However, the negative finding in *S. mutans* may be a sampling error because of the small number of subjects.

In contrast to other studies, none of our subjects with caries had detectable Scardovia without the presence of *S. mutans*. Further in this study, we found that only 6.0% (3/50) of subjects in the caries-experience group that had low level of *S. mutans* and high level of Scardovia. Therefore, although *S. mutans* was not significantly associated with caries, it is not possible to separate the presence with the significant association with Scardovia.

The universal primers used in this study were to serve as the internal control for amount of DNA obtained from each saliva sample. We used saliva rather than

plaque samples for this study to predict the bacterial component in oral cavity. Our experience with plague samples was that the amount of plague collected was too variable and therefore not as reliable in assessing the quantity of oral bacteria counts, even when normalized for total bacteria using universal primers. Further, saliva was chosen because it is more representative of the entire oral cavity rather than the selection of individual teeth<sup>53</sup>. Additionally, it has been demonstrated that saliva, being continuously in contact with all teeth, better reflects the colonization of MS on all the dentition<sup>54</sup>. In other studies, the bacterial counts from saliva samples are considered as a reflection of bacterial load from dental biofilm of individual's oral cavity<sup>18, 55, 56</sup>. The levels of MS in saliva have been shown to be a mean of predicting caries activity<sup>40, 51</sup>. It is anticipated that the use of saliva samples in our study provided a generalized picture of the microbiological load of different bacteria species, especially because the method of collection included rubbing the sterile q-tips over the teeth.

## Limitation

Our qPCR assay was limited in detecting Scardovia genus instead of being specific to *S. wiggsiae*. *Scardovia inopinata* is another potential human Scardovia species and would produce a different sized amplicon than *S. wiggsiae*. Although

this protocol for qPCR would generate two different values in melting temperature, the melting temperature of *S. inopinata* was less than 1°C higher than *S. wiggsiae*. The Scardovia primers used herein were not specifically capable of differentiating the two species.

The population in our study was limited in African Americans from a small geographic rural community, which was uniform but nonetheless the unique bacteria profile in this cohort (i.e., high level of *S. mutans*) may not be representative of other populations.

More definitive discrimination of bacterial profiles related to caries activity may have resulted with a larger sample population especially if active caries could be better differentiated and assessed (i.e., with aid of radiographs) prior to restoration/extraction of carious teeth.

## CONCLUSION

Dental caries is the most prevalent infectious disease in children. Although caries can be prevented by fluoride, sealants, optimal nutrition & dietary practices, and other measures, in the US this disease affects 28 % of children from aged 2-5 years. The cause of caries is multifactorial, dietobacterial and therefore complex. In this study, most subjects had *S. mutans* and Scardovia present from saliva samples. The level of *S. mutans* was much higher than Scardovia; however, no association was found between *S. mutans* and caries experience. The ratio of Scardovia/total bacteria was significantly higher in the caries-experience group. With *S. mutans* and Scardovia together, no clear added association was seen with caries experience.

Since caries is a multifactorial and a complex disease, other factors (i.e., diet, ethic race, social economic class) should be considered. Further, the overall profile of microbiota (i.e., more than focusing on the MS and Scardovia) may provide more relevant information related to the bacterial contribution to a caries risk assessment.

## REFERENCES

- Beltrán-Aguilar ED, Barker LK, Canto MT, et al. Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ 2005;54(3):1-43.
- Oral health in America: a report of the surgeon general. Rockville, MD: National Institutes of Health, National Institute of Dental and Craniofacial Research, U.S. Department of Health and Human Services; 2000.
- 3. Dye BA, Tan S, Smith V, et al. Trends in oral health status: United States, 1988-1994 and 1999-2004. Vital Health Stat 11 2007(248):1-92.
- 4. Policy on Early Childhood caries(ECC): Classification, Consequences, and Preventive stragtegies: Pediatric Dentistry; 2012/13. p. 50-52.
- 5. Gift HC, Reisine ST, Larach DC. The social impact of dental problems and visits. Am J Public Health 1992;82(12):1663-8.
- 6. Blumenshine SL, Vann WF, Gizlice Z, Lee JY. Children's school performance: impact of general and oral health. J Public Health Dent 2008;68(2):82-7.
- 7. Filstrup SL, Briskie D, da Fonseca M, et al. Early childhood caries and quality of life: child and parent perspectives. Pediatr Dent 2003;25(5):431-40.
- 8. Ramos-Gomez FJ, Huang GF, Masouredis CM, Braham RL. Prevalence and treatment costs of infant caries in Northern California. ASDC J Dent Child 1996;63(2):108-12.
- Griffin SO, Gooch BF, Beltrán E, Sutherland JN, Barsley R. Dental services, costs, and factors associated with hospitalization for Medicaid-eligible children, Louisiana 1996-97. J Public Health Dent 2000;60(1):21-7.

- 10. Theilade E. The non-specific theory in microbial etiology of inflammatory periodontal diseases. J Clin Periodontol 1986;13(10):905-11.
- 11. Loesche WJ. The specific plaque hypothesis and the antimicrobial treatment of periodontal disease. Dent Update 1992;19(2):68, 70-2, 74.
- 12. Marsh PD. Microbial ecology of dental plaque and its significance in health and disease. Adv Dent Res 1994;8(2):263-71.
- 13. Van Houte J. Role of micro-organisms in caries etiology. J Dent Res 1994;73(3):672-81.
- 14. Tanzer JM, Livingston J, Thompson AM. The microbiology of primary dental caries in humans. J Dent Educ 2001;65(10):1028-37.
- 15. Loesche WJ. Role of *Streptococcus mutans* in human dental decay. Microbiol Rev 1986;50(4):353-80.
- 16. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol 2010;192(19):5002-17.
- Hughes CV, Dahlan M, Papadopolou E, et al. Aciduric microbiota and mutans streptococci in severe and recurrent severe early childhood caries. Pediatr Dent 2012;34(2):e16-23.
- 18. Nurelhuda NM, Al-Haroni M, Trovik TA, Bakken V. Caries experience and quantification of *Streptococcus mutans* and *Streptococcus sobrinus* in saliva of Sudanese schoolchildren. Caries Res 2010;44(4):402-7.
- 19. Choi EJ, Lee SH, Kim YJ. Quantitative real-time polymerase chain reaction for *Streptococcus mutans* and *Streptococcus sobrinus* in dental plaque samples and its association with early childhood caries. Int J Paediatr Dent 2009;19(2):141-7.
- Kishi M, Abe A, Kishi K, et al. Relationship of quantitative salivary levels of Streptococcus mutans and S. sobrinus in mothers to caries status and colonization of mutans streptococci in plaque in their 2.5-year-old children. Community Dent Oral Epidemiol 2009;37(3):241-9.

- Childers NK, Osgood RC, Hsu KL, et al. Real-time quantitative polymerase chain reaction for enumeration of *Streptococcus mutans* from oral samples. Eur J Oral Sci 2011;119(6):447-54.
- 22. Ge Y, Caufield PW, Fisch GS, Li Y. *Streptococcus mutans* and *Streptococcus sanguinis* colonization correlated with caries experience in children. Caries Res 2008;42(6):444-8.
- 23. Teanpaisan R, Thitasomakul S, Piwat S, et al. Longitudinal study of the presence of mutans streptococci and lactobacilli in relation to dental caries development in 3-24 month old Thai children. Int Dent J 2007;57(6):445-51.
- 24. Banas JA. Virulence properties of *Streptococcus mutans*. Front Biosci 2004;9:1267-77.
- 25. Zero DT. Sugars the arch criminal? Caries Res 2004;38(3):277-85.
- 26. Islam B, Khan SN, Khan AU. Dental caries: from infection to prevention. Med Sci Monit 2007;13(11):RA196-203.
- Beighton D. The complex oral microflora of high-risk individuals and groups and its role in the caries process. Community Dent Oral Epidemiol 2005;33(4):248-55.
- 28. Aas JA, Griffen AL, Dardis SR, et al. Bacteria of dental caries in primary and permanent teeth in children and young adults. J Clin Microbiol 2008;46(4):1407-17.
- 29. Becker MR, Paster BJ, Leys EJ, et al. Molecular analysis of bacterial species associated with childhood caries. J Clin Microbiol 2002;40(3):1001-9.
- Munson MA, Banerjee A, Watson TF, Wade WG. Molecular analysis of the microflora associated with dental caries. J Clin Microbiol 2004;42(7):3023-9.
- 31. Tanner AC, Mathney JM, Kent RL, et al. Cultivable anaerobic microbiota of severe early childhood caries. J Clin Microbiol 2011;49(4):1464-74.

- 32. Kanasi E, Dewhirst FE, Chalmers NI, et al. Clonal analysis of the microbiota of severe early childhood caries. Caries Res 2010;44(5):485-97.
- 33. Downes J, Mantzourani M, Beighton D, et al. Scardovia wiggsiae sp. nov., isolated from the human oral cavity and clinical material, and emended descriptions of the genus Scardovia and Scardovia inopinata. Int J Syst Evol Microbiol 2011;61(Pt 1):25-9.
- 34. Kressirer C, King W, Dobeck J, et al. *Scardovia wiggsiae* Cariogenicity Test in an Animal Model. J Dent Res 84(Spec Iss A):1030, 2013
- 35. Mantzourani M, Gilbert SC, Sulong HN, et al. The isolation of bifidobacteria from occlusal carious lesions in children and adults. Caries Res 2009;43(4):308-13.
- Tanner AC, Kent RL, Holgerson PL, et al. Microbiota of severe early childhood caries before and after therapy. J Dent Res 2011;90(11):1298-305.
- 37. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6(10):986-94.
- Nonnenmacher C, Dalpke A, Rochon J, et al. Real-time polymerase chain reaction for detection and quantification of bacteria in periodontal patients. J Periodontol 2005;76(9):1542-9.
- 39. Psoter WJ, Ge Y, Russell SL, et al. PCR detection of *Streptococcus mutans* and *Aggregatibacter actinomycetemcomitans* in dental plaque samples from Haitian adolescents. Clin Oral Investig 2011;15(4):461-9.
- 40. Yano A, Kaneko N, Ida H, Yamaguchi T, Hanada N. Real-time PCR for quantification of *Streptococcus mutans*. FEMS Microbiol Lett 2002;217(1):23-30.
- 41. Hata S, Hata H, Miyasawa-Hori H, Kudo A, Mayanagi H. Quantitative detection of Streptococcus mutans in the dental plaque of Japanese preschool children by real-time PCR. Lett Appl Microbiol 2006;42(2):127-31.

- 42. Tanner AC, Sonis AL, Lif Holgerson P, et al. White-spot lesions and gingivitis microbiotas in orthodontic patients. J Dent Res 2012;91(9):853-8.
- 43. Organization WH. WHO: Oral health surveys-basic methods, ed 4th.Geneva; 1997.
- 44. Syed SA, J LW. Survival of Human Dental Plaque Flora in Various Transport Fluid: Applied Microbiology; Oct. 1972. p. 638-44.
- 45. Yoshida A, Suzuki N, Nakano Y, et al. Development of a 5' nuclease-based real-time PCR assay for quantitative detection of cariogenic dental pathogens *Streptococcus mutans* and *Streptococcus sobrinus*. J Clin Microbiol 2003;41(9):4438-41.
- 46. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 2002;148(Pt 1):257-66.
- 47. Rôças IN, Siqueira JF. Characterization of microbiota of root canal-treated teeth with posttreatment disease. J Clin Microbiol 2012;50(5):1721-4.
- Hornby K, Oakley C. Critical Thinking-Understanding and Evaluating Dental Research. Second Edition ed: Quintessence Publishing Co, Inc; 2007.
- 49. Loyola-Rodriguez JP, Martinez-Martinez RE, Flores-Ferreyra BI, et al. Distribution of *Streptococcus mutans* and *Streptococcus sobrinus* in saliva of Mexican preschool caries-free and caries-active children by microbial and molecular (PCR) assays. J Clin Pediatr Dent 2008;32(2):121-6.
- Zhao D, Wang ZY, Wang JQ, Xiao B, Zhou Y. Quantitative detection of Streptococcus mutans in different people with dental caries by real-time polymerase chain reaction]. Zhonghua Kou Qiang Yi Xue Za Zhi 2010;45(4):223-7.
- 51. Vieira AR, Deeley KB, Callahan NF, et al. Detection of *Streptococcus mutans* Genomic DNA in Human DNA Samples Extracted from Saliva and Blood. ISRN Dent 2011;2011:543561.

- 52. Acevedo AM, Ray MV, Socorro M, Rojas-Sánchez F. Frequency and distribution of Mutans Streptococci in dental plaque from caries-free and caries-affected Venezuelan children. Acta Odontol Latinoam 2009;22(1):15-20.
- 53. Lindquist B, Emilson CG. Distribution and prevalence of mutans streptococci in the human dentition. J Dent Res 1990;69(5):1160-6.
- 54. Emilson CG. Prevalence of *Streptococcus mutans* with different colonial morphologies in human plaque and saliva. Scand J Dent Res 1983;91(1):26-32.
- 55. Price RR, Viscount HB, Stanley MC, Leung KP. Targeted profiling of oral bacteria in human saliva and in vitro biofilms with quantitative real-time PCR. Biofouling 2007;23(3-4):203-13.
- 56. Dasanayake AP, Caufield PW, Cutter GR, Roseman JM, Köhler B. Differences in the detection and enumeration of mutans streptococci due to differences in methods. Arch Oral Biol 1995;40(4):345-51.

APPENDIX

**IRB APPROVAL FORMS** 

RLAB

Characterization of the IRB approval before implementing proposed changes. See Section 14 of the IRB Guidebook for Investigators for additional information.

Change means any change, in content or form, to the protocol, consent form,	or any supportive materials (such as the Investigator's
Brochure, questionnaires, surveys, advertisements, etc.). See Item 4 for more	examples.

2. Principal Investig			
A CONTRACTOR OF	ator (PI)		
Name (with degree)	Noel K. Childers, DDS, MS, PhD	Blazer ID	nkc
Department	Pediatric Dentistry	Division (if applicable)	
Office Address	SDB 304	Office Phone	934-3230
E-mail	nkc@uab.edu	Fax Number	934-7013
Contact person who sh Name Phone	ould receive copies of IRB correspon Tonya Wiley 934-6211 Office Address (if different from PI)	ndence (Optional) E-Mail Fax Number	tnett@uab.edu 934-7013
3. UAB IRB Protoco	Identification		
3.a. Protocol Numbe	F060328001		
3.b. Protocol Title	Epidemiology of Dental Ca	aries and Immunity in Chil	dren (Alabama)
3.c. Current Status	of Protocol—Check ONE box at left;	provide numbers and date	where applicable
Study has not yet I	begun No participants,	data, or specimens have b	een entered.
In progress; open	o accrual Number of par	ticipants, data, or specime	ns entered: 925
Enrollment tempor	arily suspended by sponsor		
Date closed:	Number o Number of pa	f participants receiving inte	erventions:
Closed to accrual, Date closed:	and only data analysis continues	rticipants in long-term folic Total number of participan	w-up only: ts entered:
Closed to accrual, Date closed: Date closed	and only data analysis continues hange that apply, and describe the c eview, please ensure that you provid ked. Change in the IRB-approved protoco able, provide sponsor's protocol version nt (addition to the IRB-approved pro able, provide funding application docum to umber, undate number, etc.	rticipants in long-term folic Total number of participan hanges in Item 5.c. or 5.d. a e the required materials an l) number, amendment numb tocol) nent from sponsor, as well as	w-up only: ts entered: as applicable. To help d/or information for each er, update number, etc. sponsor's protocol version

FOR 224

Page 1 of 3

A Ir si if A A T IF	Add or remove performance sites n Item 5.c., identify the site and location, and describe the research-related procedures performed there. If adding site(s), attach notification of permission or IRB approval to perform research there. Also include copy of subcontract f applicable. If this protocol includes acting as the Coordinating Center for a study, attach IRB approval from any include site added. Vdd or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) To assist you in revising or preparing your submission, please see the IRB Guidebook for Investigators or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to the submission of protection of the submission of the subm
Ir si if n A A T IF	n Item 5.c., identify the site and location, and describe the research-related procedures performed there. If adding site(s), attach notification of permission or IRB approval to perform research there. Also include copy of subcontract f applicable. If this protocol includes acting as the Coordinating Center for a study, attach IRB approval from any ton-UAB site added. Ndd or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) To assist you in revising or preparing your submission, please see the IRB Guidebook for Investigators or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to be approved by the samples approved to be approved to be approved by the samples approved to be approved by the samples approved by the samples (IRB approved to be approved by the samples)
si if A A T IF S S	site(s), attach notification of permission or IRB approval to perform research there. Also include copy of subcontract f applicable. If this protocol includes acting as the Coordinating Center for a study, attach IRB approval from any ion-UAB site added. Add or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) To assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to
if A T 	f applicable. If this protocol includes acting as the Coordinating Center for a study, attach IRB approval from any on-UAB site added. Add or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) o assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to
n A T S Ir	non-UAB site added. Add or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) To assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the <u>RB office at 934-3789.</u> Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval t
A IF S Ir	Add or change a genetic component or storage of samples and/or data component—this could include data submissions for Genome-Wide Association Studies (GWAS) Fo assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to
T 	submissions for Genome-Wide Association Studies (GWAS) Fo assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to
T    <del> </del> S	Fo assist you in revising or preparing your submission, please see the <u>IRB Guidebook for Investigators</u> or call the RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval to
lf S Ir	RB office at 934-3789. Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval t
s lr	Suspend, re-open, or permanently close protocol to accrual of individuals, data, or samples (IRB approval t
lr	
Ir	remain active)
	n Item 5.c., indicate the action, provide applicable dates and reasons for action; attach supporting documentation.
R	Report being forwarded to IRB (e.g., DSMB, sponsor or other monitor)
lr	n Item 5.c., include date and source of report, summarize findings, and indicate any recommendations.
R	Revise or amend consent, assent form(s)
C C	Complete Item 5.d.
A	Addendum (new) consent form
C	Complete Item 5.d.
A	Add or revise recruitment materials
C	Complete Item 5.d.
	Other (e.g., investigator brochure)
-Ir	ndicate the type of change in the space below, and provide details in Item 5.c. or 5.d. as applicable.
Ir	nclude a copy of all affected documents, with revisions highlighted as applicable.
Ye	es No 5.a. Are any of the participants enrolled as normal, healthy controls?
	If yes, describe in detail in Item 5.c. how this change will affect those participants.
Ye	$\gtrsim$ $\sum N_0$ 5.b. Does the change affect subject participation, such as procedures, risks, costs, location of
	services, etc.?
	If yes, FAP-designated units complete a FAP submission and send to <u>tap@uab.edu</u> . Identify the
	FAP-designated unit in Item 5.c.
	For more details on the UAB FAP, see www.uab.edu/cto.
5.C. Pr	rotocol changes: in the space below, briefly describe—and explain the reason for—all change(s) to the
pr	QUOCOL.
	We are adding the following personnel: Kelsey Jordan, Devon Cooper, Leanne Bowman, Vanessa
	Freitas, Jung-yi Liu, Carter Thomas, Priya Gulati and Marina A. Perez. Current IRB training records fo
	all are attached. Records are already on file for Marina A. Perez.
5.d. C	onsent and Recruitment Changes. In the space below.
2	) describe all changes to IRB-approved forms or recruitment materials and the reasons for them:
(a)	
(a, (b)	I describe the reasons for the addition of any materials (e.g. addendum consent, recruitment); and
(a) (b) (c)	) describe the reasons for the addition of any materials (e.g., addendum consent, recruitment); and ) indicate either how and when you will reconsent enrolled participants or why reconsenting is not
(a) (b) (c) ne	<ul> <li>b) describe the reasons for the addition or any materials (e.g., addendum consent, recruitment); and         indicate either how and when you will reconsent enrolled participants or why reconsenting is not         cessary (not applicable for recruitment materials).</li> </ul>
(a) (b) (c) ne	<ul> <li>b) describe the reasons for the addition or any materials (e.g., addendum consent, recruitment); and</li> <li>c) indicate either how and when you will reconsent enrolled participants or why reconsenting is not accessary (not applicable for recruitment materials).</li> </ul>
(a) (b) (c) ne Al:	b) gescribe the reasons for the addition of any materials (e.g., addendum consent, recruitment); and ) indicate either how and when you will reconsent enrolled participants or why reconsenting is not acessary (not applicable for recruitment materials). so, indicate the number of forms changed or added. For new forms, provide 1 conv. For revised
(a) (b) (c) ne Al: do	b) describe the reasons for the addition of any materials (e.g., addendum consent, recruitment); and ) indicate either how and when you will reconsent enrolled participants or why reconsenting is not acessary (not applicable for recruitment materials). Iso, indicate the number of forms changed or added. For new forms, provide 1 copy. For revised accuments, provide 3 copies:
(a) (b) (c) ne Al: do • a	<ul> <li>accrube the reasons for the addition of any materials (e.g., addendum consent, recruitment); and</li> <li>indicate either how and when you will reconsent enrolled participants or why reconsenting is not accessary (not applicable for recruitment materials).</li> <li>iso, indicate the number of forms changed or added. For new forms, provide 1 copy. For revised accuments, provide 3 copies:</li> <li>is copy of the currently approved document (showing the IRB approval stamp. if applicable)</li> </ul>
(a) (b) (c) ne Al: do • a	<ul> <li>b) describe the reasons for the addition or any materials (e.g., addendum consent, recruitment); and</li> <li>c) indicate either how and when you will reconsent enrolled participants or why reconsenting is not accessary (not applicable for recruitment materials).</li> <li>so, indicate the number of forms changed or added. For new forms, provide 1 copy. For revised accessing, provide 3 copies:</li> <li>1 copy of the currently approved document (showing the IRB approval stamp, if applicable)</li> <li>1 revised copy highlighting all proposed changes with "tracked" changes.</li> </ul>
(a) (b) (c) ne Al: do • a • a • a	<ul> <li>b) describe the reasons for the addition or any materials (e.g., addendum consent, recruitment); and</li> <li>c) indicate either how and when you will reconsent enrolled participants or why reconsenting is not accessary (not applicable for recruitment materials).</li> <li>lso, indicate the number of forms changed or added. For new forms, provide 1 copy. For revised ocuments, provide 3 copies:</li> <li>a copy of the currently approved document (showing the IRB approval stamp, if applicable)</li> <li>t revised copy highlighting all proposed changes with "tracked" changes</li> <li>t revised copy of the IRB approval stamp.</li> </ul>
(a) (b) (c) ne Al: do • a • a • a	<ul> <li>b) describe the reasons for the addition or any materials (e.g., addendum consent, recruitment); and</li> <li>c) indicate either how and when you will reconsent enrolled participants or why reconsenting is not accessary (not applicable for recruitment materials).</li> <li>lso, indicate the number of forms changed or added. For new forms, provide 1 copy. For revised ocuments, provide 3 copies:</li> <li>a copy of the currently approved document (showing the IRB approval stamp, if applicable)</li> <li>a revised copy highlighting all proposed changes with "tracked" changes</li> <li>a revised copy for the IRB approval stamp.</li> </ul>

FOR 224

.

Page 2 of 3

FOR IRB USE ONLY	
Received & Noted Approved Expedited*	□ To Convened IRB
Signature (Chair, Vice-Chair, Designee)	
DOLA 9-28-11	JUN 1 1 2012
Change to Expedited Category Y / N / NA	OFFICE OF INSTITUTIONAL

FOR 224

Page 3 of 3 Page 3 of 3

Protoc	tion of Human Subjects
Assurance Identification/	IRB Certification/Declaration of Exemption (Common Rule)
Policy: Research activities involving human subjects may not be conducted the Departments and Agencies adopting the Common Rule (56FR28003, unless the activities are exempt from or approved in accordance with the Cor section 101(b) of the Common Rule for exemptions. Institutions submitting proposals for support must submit certification of appropriate Institutional Rev review and approval to the Department or Agency in accordance with the Co	or supported by Institutions must have an assurance of compliance that applies to the research to bu June 18, 1991) conducted and should submit certification of IRB review and approval with each application or mmon Rule. See proposal unless otherwise advised by the Department or Agency. Japplications or Jaw Board (IRB) Common Rule.
1. Request Type       2. Type of Mechanism         [] ORIGINAL       [] GRANT CONTRACT [] F         ***CONTINUATION       [] COOPERATIVE AGREEMENT         [] EXEMPTION       [] OTHER:	3. Name of Federal Department or Agency and, if known, FELLOWSHIP Application or Proposal Identification No.
<ol> <li>Title of Application or Activity pidemiology of Dental Caries and Immunity in Children (Alabama)</li> </ol>	5. Name of Principal Investigator, Program Director, Fellow, or Other CHILDERS, NOEL
X This Assurance, on file with Department of Health and Hum	an Services, covers this activity: _, the expiration date01/24/2017IRB Registration NoIRB00000726
1 This Assurance on file with (agency/denfi	. covers this activity
[] This Assurance, on file with (agency/dept) Assurance No, the expiration da [] No assurance has been filed for this institution. This instituti approval upon request. [] Exemption Status: Human subjects are involved, but this ac	ate, covers this activity ate IRB Registration/Identification No, covers this activity ion declares that it will provide an Assurance and Certification of IRB review and ctivity qualifies for exemption under Section 101(b), paragraph
[] This Assurance, on file with (agency/dept)	, covers this activity ateIRB Registration/Identification No(if applicable, ion declares that it will provide an Assurance and Certification of IRB review and ctivity qualifies for exemption under Section 101(b), paragraph g IF you have an Assurance on file) n accordance with the Common Rule and any other governing regulations. 112or [] Expedited Review on (date) ion date e not been reviewed. The IRB has granted approval on condition that all projects ved before they are initiated and that appropriate further certification will be submitted.
[] This Assurance, on file with (agency/dept)	, covers this activity ateIRB Registration/Identification No(if applicable ion declares that it will provide an Assurance and Certification of IRB review and ctivity qualifies for exemption under Section 101(b), paragraph g IF you have an Assurance on file) in accordance with the Common Rule and any other governing regulations. 112 or [] Expedited Review on (date) ion date e not been reviewed. The IRB has granted approval on condition that all projects ved before they are initiated and that appropriate further certification will be submitted. Title F060328001
[] This Assurance, on file with (agency/dept) Assurance No, the expiration di [] No assurance has been filed for this institution. This institut approval upon request. [] Exemption Status: Human subjects are involved, but this ac 7. Certification of IRB Review (Respond to one of the following [] This activity has been reviewed and approved by the IRB in by: [] Full IRB Review on (date of IRB meeting). 8/29/20 [] If less than one year approval, provide expirati [] This activity contains multiple projects, some of which have covered by the Common Rule will be reviewed and approv 8. Comments Protocol subject to Annual continuing review. IRB Approval Issued:	, covers this activity ateIRB Registration/Identification No(if applicable ion declares that it will provide an Assurance and Certification of IRB review and ctivity qualifies for exemption under Section 101(b), paragraph g IF you have an Assurance on file) in accordance with the Common Rule and any other governing regulations. 112 or [] Expedited Review on (date) ion date e not been reviewed. The IRB has granted approval on condition that all projects ved before they are initiated and that appropriate further certification will be submitted. Title F060328001 Epidemiology of Dental Caries and Immunity in Children (Alabama)
[] This Assurance, on file with (agency/dept) Assurance No, the expiration di approval upon request.         [] No assurance has been filed for this institution. This institut approval upon request.         [] Exemption Status: Human subjects are involved, but this activity has been reviewed and approved by the IRB in by: [X] Full IRB Review (Respond to one of the following [X] This activity has been reviewed and approved by the IRB in by: [X] Full IRB Review on (date of IRB meeting) 8/29/20 [] If less than one year approval, provide expirating [] This activity contains multiple projects, some of which have covered by the Common Rule will be reviewed and approval 8. Comments Protocol subject to Annual continuing review.         IRB Approval Issued:       09-12-12_         9. The official signing below certifies that the information provid correct and that, as required, future reviews will be performed closure and certification will be provided.	, covers this activity ate IRB Registration/Identification No
<ul> <li>[] This Assurance, on file with (agency/dept)</li></ul>	
[] This Assurance, on file with (agency/dept)	
[] This Assurance, on file with (agency/dept) Assurance No, the expiration di approval upon request.         [] No assurance has been filed for this institution. This institut approval upon request.         [] Exemption Status: Human subjects are involved, but this activity has been reviewed and approved by the IRB in by: [M] Full IRB Review (Respond to one of the following [M] This activity has been reviewed and approved by the IRB in by: [M] Full IRB Review on (date of IRB meeting) 8/29/20 [] If less than one year approval, provide expirating [] This activity contains multiple projects, some of which have covered by the Common Rule will be reviewed and approval 8. Comments Protocol subject to Annual continuing review.         IRB Approval Issued: <u>09-12-12</u> 9. The official signing below certifies that the information provi correct and that, as required, future reviews will be performed closure and certification will be provided.         11. Phone No. (with area code)       (205) 934-1301         13. Email:       irb@uab.edu	
[] This Assurance, on file with (agency/dept) Assurance No, the expiration di approval upon request.         [] No assurance has been filed for this institution. This institut approval upon request.         [] Exemption Status: Human subjects are involved, but this activity has been reviewed and approved by the IRB in by: [X] Full IRB Review (Respond to one of the following [X] This activity has been reviewed and approved by the IRB in by: [X] Full IRB Review on (date of IRB meeting) 8/29/20 [] If less than one year approval, provide expirati [] This activity contains multiple projects, some of which have covered by the Common Rule will be reviewed and approv 8. Comments Protocol subject to Annual continuing review.         IRB Approval Issued: $09 - 12 - 12$ .         9. The official signing below certifies that the information provid covered and that, as required, future reviews will be performed closure and certification will be provided.         11. Phone No. (with area code)       (205) 934-1301         13. Email:       irb@uab.edu         14. Name of Official Ferdinand Urthaler, M.D.	

			OMB No. 0990
	Drotosti	an of Livera	Approved for use through 3/31/
Δ	Assurance Identification/IR	B Certificat (Common Ru	n Subjects ion/Declaration of Exemption le)
Policy: Research activities in the Departments and Agen unless the activities are ex- section 101 (b) of the Com- proposals for support must review and approval to the	involving human subjects may not be conducted or s notes adopting the Common Rule (56FR2803, Jun- mant from crapproved in accordracewith he Comm mon Rule for exemptions. Institutions submittig ap submit certification of appropriate histitutional Raview Department or Agency in accordance with the Com	supported by Institution en 16, 1991) conduct on Rule See proposa plications or Board (IRB) mon Rule.	ns must have an assurance of compliance that applies to the researc ad and should submit catlification of IRB review and approval with each apple luniess otherwise advised by the Department or Agency.
1. Request Type [] ORIGINAL CONTINUATION [] EXEMPTION	2. Type of Mechanism [] GRANT [] CONTRACT [] FEI [] COOPERATIVE AGREEMENT [] OTHER:	LOWSHIP	<ol> <li>Name of Federal Department or Agency and, if known, Application or Proposal Identification No.</li> </ol>
4. Title of Application o Epidemiology of Dental Cari	r Activity es and Immunity in Children (Alabama)		5. Name of Principal Investigator, Program Director, Fellow, Other CHILDERS, NOEL
6. Assurance Status of f	this Project (Respond to one of the followi	ng)	
This Assurance, on f	ie with Department of Health and Human	Services, covers the	is activity: 01/24/2017 IRB Registration No. IRB00000726
	, 41	e expliation date	The Registration No
[] This Assurance, on f Assurance No	le with (agency/dept), the expiration date	IRB	Registration/Identification No, covers this ac
<ul> <li>[] This Assurance, on f Assurance No</li> <li>[] No assurance has be approval upon request</li> </ul>	le with (agency/dept)the expiration datethe expiration date_ een filed for this institution. This institution st.	IRB declares that it will	Registration/Identification No, covers this ac fif applic provide an Assurance and Certification of IRB review and
[] This Assurance, on f Assurance No [] No assurance has be approval upon reques [] Exemption Status: Hu	We with (agency/dept)the expiration datethe expiration datethe stitution. This institution st.	declares that it will the declares that it will the declares that it will be declared by qualifies for exerting the declared by qualifi	Registration/Identification No, covers this ar provide an Assurance and Certification of IRB review and nption under Section 101(b), paragraph
This Assurance, on f Assurance No     No assurance has be approval upon reques     Exemption Status: Hi     Certification of IRB Re	le with (agency/dept), the expiration date, the expiration date, the spiration	declares that it will the declares that it will the declares that it will be declared by the d	, covers this a Registration/Identification No(if applic provide an Assurance and Certification of IRB review and notion under Section 101(b), paragraph ance on file)
<ol> <li>This Assurance, on f Assurance No</li> <li>No assurance has be approval upon request</li> <li>Exemption Status: Hu</li> <li>Certification of IRB Ru</li> <li>This activity has bee by. M Full IRB Ru</li> </ol>	le with (agency/dept)the expiration datethe expiration datethe expiration date sen filed for this institution. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF in reviewed and approved by the IRB in ac eview on (date of IRB meeting) 8/7/2013	declares that it will ty qualifies for exer you have an Assur cordance with the or [] i	, covers this ar Registration/Identification No, covers this ar provide an Assurance and Certification of IRB review and mption under Section 101(b), paragraph ance on file) Common Rule and any other governing regulations. Expedited Review on (date)
<ul> <li>[] This Assurance, on f Assurance No</li> <li>[] No assurance has be approval upon request</li> <li>[] Exemption Status: Hu</li> <li>7. Certification of IRB Rd</li> <li>[] This activity has been by: [] Full IRB Rd</li> <li>[] This activity contains covered by the Corr</li> </ul>	le with (agency/dept)the expiration datethe expiration datethe expiration date sen filed for this institution. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF an reviewed and approved by the IRB in ac eview on (date of IRB meeting) 8/7/2013 an one year approval, provide expiration of im tiple projects, some of which have no imon Rule will be reviewed and approved	declares that it will ty qualifies for exer you have an Assur cordance with the or []1 datetbeen reviewed. T before they are init	, covers this ar Registration/Identification No
<ul> <li>[] This Assurance, on f Assurance No</li></ul>	le with (agency/dept)	y qualifies for exer you have an Assur cordance with the date or [] I before they are init Title F Epidemioi	, covers this ac Registration/Identification No
<ul> <li>[] This Assurance, on f Assurance No</li></ul>	le with (agency/dept)the expiration datethe expiration datethe expiration datethe expiration. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF an reviewed and approved by the IRB in ac eview on (date of IRB meeting) 8/7/2013 an one year approval, provide expiration of an one year approval, provide expiration of an one year approval, provide expiration of multiple projects, some of which have no mon Rule will be reviewed and approved ual continuing review. d?: No pproved?: No	IRB declares that it will by qualifies for exer you have an Assur cordance with the cordance with the date or []1 date t been reviewed. T before they are init Title f Epidemiol	, covers this ac Registration/Identification No
<ul> <li>[] This Assurance, on f Assurance No</li> <li>[] No assurance has be approval upon reque:</li> <li>[] Exemption Status: He</li> <li>[] Exemption Status: He</li> <li>7. Certification of IRB R.</li> <li>[] This activity has bee by. [] Fill IRB R.</li> <li>[] This activity has bee by. [] Hell IRB R.</li> <li>[] If less th</li> <li>[] This activity contains covered by the Corr</li> <li>8. Comments</li> <li>Protocol subject to Annu- HIPAA Waiver Approve</li> <li>Partial HIPAA Waiver A</li> <li>IRB Approval Issued:</li> </ul>	ie with (agency/dept)the expiration datethe expiration datethe expiration datethe expiration. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF in reviewed and approved by the IRB in ac eview on (date of IRB meeting) 8/7/2013 han one year approval, provide expiration of imultiple projects, some of which have no imon Rule will be reviewed and approved ual continuing review. d?: No pproved?: No II	IRB declares that it will by qualifies for exer you have an Assur cordance with the or []] date or []] date or []] tbeen reviewed. T before they are in Title F Epidemiol IRB Appro	, covers this ac Registration/Identification No
<ol> <li>This Assurance, on f Assurance No</li></ol>	le with (agency/dept)the expiration datethe expiration datethe expiration datethe expiration datethe expiration. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF in reviewed and approved by the IRB in ac eview on (date of IRB meeting) 8/7/2013 han one year approval, provide expiration of imultiple projects, some of which have no imon Rule will be reviewed and approved ual continuing review. d?: No pproved?: No $\frac{1}{2} \frac{1}{14}$ thom certifies that the information provided lired, future reviews will be performed unit will be provided.	IRB declares that it will by qualifies for exer you have an Assur cordance with the or []] date or []] tbeen reviewed. T before they are in before they are in Title F Epidemiol IRB Appro above is 10. Nan I study	, covers this ac Registration/Identification No
<ol> <li>This Assurance, on f Assurance No</li></ol>	le with (agency/dept)	you have an Assur you have an Assur cordance with the or []1 date or []1 date or []1 toen reviewed. T before they are init Title Epidemiol IRB Appro IRB Appro IRB Appro	, covers this ac Registration/Identification No
<ol> <li>This Assurance, on f Assurance No</li></ol>	le with (agency/dept)	IRB declares that it will by qualifies for exern you have an Assur coordance with the or []1 date or []1 d	, covers this ac Registration/Identification No
<ul> <li>[] This Assurance, on f Assurance No</li></ul>	le with (agency/dept)the expiration datethe expiration datethe expiration datethe expiration datethe expiration datethe expiration of the solution. This institution st. uman subjects are involved, but this activit eview (Respond to one of the following IF in reviewed and approved by the IRB in acc view on (date of IRB meeting) 8/7/2013 han one year approval, provide expiration of imultiple projects, some of which have no immon Rule will be reviewed and approved ual continuing review. d?: No pproved?: No $\frac{1}{2} 1 \frac{1}{14}$ How certifies that the information provided itied, future reviews will be performed unti will be provided. a code) (205) 934-1301 inb@uab.edu	Adeclares that it will declares that it will by qualifies for exer you have an Assur cordance with the cordance with the or []] dateor []] dateor []] tbeen reviewed. T before they are init Title F Epidemiol IRB Appro IRB Appro above is 10. Nan I study Univ 701 Birm	
<ul> <li>[] This Assurance, on f Assurance No</li></ul>	le with (agency/dept)	IRB declares that it will ty qualifies for exer you have an Assur cordance with the date or []1 date or []1 fittle F Epidemiol IRB Appro IRB Appro IRB Appro IRB It Unit Title I IRB Appro IRB A	